Member Info for one4one

Hemogenyx science is Autologous a custom 121 therapy and is not scalable for a host of reasons.

TO commercial Scale is changing the science from Autologous to Allogeneic.

then the present clinical trial will be sanctioned with a clinical Hold🐭

Thinks the tungsten play is noise until the Mre /no doubt the institutes will get first pick for future cash raises/ a distant thought that gwmo will by-pass the bucket shop and offer lth the opp to raise ie:primary bid

Natural killer cells, they do not require antigen priming.......they act fast & more broadly.

they are naturally allogeneic-friendly....... unlike T-Cells Nk cells do not cause graft v host disease.

Lower Crs & neurotoxicity/Nk cells can be tuned with Nk signalling (2b4...DA10..Dap12 domains !

Cancer needs a therapy that works every time for everyone. On Demand & that is not autologous Thats allogeneic/NK cells was not invented- they evolved for this purpose. the future belongs to cells that do not care who the cohort is don`t need weeks of manufacturing/Autologous is the past, Allogeneic is the present....Nk is the future/Autologous cell therapy is not a buisiness model- it is a bottleneck disguised as a product ,investors should not get locked in to a platform that gets more fragile as demand increases ,Autologous defenders are ramping a cancer therapy which is slow expensive & limited capacity

Autologous therapy have had there moment they have proved a concept opened a door & showed what cell therapy can do, BP will monitor what can work reliably/repeatedly & at scale not a one off custom Autologous therapy that can not be scaled up & definitely not economical,

The Scalable future of this evolving industry is Allogeneic Natural Killer Cells, enjoy the easter break be careful your cells/eggs are not fertilised 🐭

So lets move on to present times, 12 months the c/t has enrolled 3/18 cohorts and the news is radio silence,

Some say hemo has raised and is cash rich/v/lad has said c5m by the year end for the c/t to progress/ year end is that the definition of before the new tax year ? if so the Cash burn is smouldering but i would not hesitate to say the warrants will be exercised as financle first aid /the market will adjust the sp to the placings price /Enrolling 3 out of 18 adult cohorts over a 12‑month period is a positive step, but it also highlights how much further the trial still needs to progress. to conclude a collaboration or placings is on the menu🐭.

CAR‑T cell therapy has now received FDA Breakthrough Therapy Designation, and allogeneic approaches are progressing globally as part of the broader scientific effort to defeat cancer.

As I’ve mentioned before, and as the record shows, long before Hemogenyx entered the field there were already clinical trials and collaborations that had advanced further. Major biopharma companies continue to monitor developments carefully before making any commitments. It’s worth remembering that Hemogenyx initially pursued a lupus collaboration, which ultimately dissolved, and the company then shifted its focus toward CDX. That program remains at an early, preclinical stage, and once again Hemogenyx pivoted—this time toward CAR‑T.

Enrolling 3 out of 18 adult cohorts over a 12‑month period is a positive step, but it also highlights how much further the trial still needs to progress. With 15 adult cohorts remaining, not to mention the infant cohorts, the clinical pathway is long. By the time these studies mature, the broader scientific landscape will likely have evolved significantly, potentially leaving Hemogenyx’s platform overshadowed by faster‑moving or more advanced competitors/technologyEnrolling 3 out of 18 adult cohorts over a 12‑month period is a positive step, but it also highlights how much further the trial still needs to progress. With 15 adult cohorts remaining, not to mention the infant cohorts, the clinical pathway is long. By the time these studies mature, the broader scientific landscape will likely have evolved significantly, potentially leaving Hemogenyx’s platform overshadowed by faster‑moving or more advanced competitors.🐭

Car-t is evolving......Autologous v allogeneic

Autologous takes 3-4 weeks to engineer the patients own cells

Allogeneic" ready made off the shelf could be life saving this shift is more cost effect 20k compared to Autologous 450k

Allogeneic of the shelf ready made therapy which is accessible quick & cost effective !

Autologous....slow....3-4 weeks to custom manufacture......costly Autologous = personalised but slow & not accessible patients may decline while waiting

and when the cancer is moving fast....Speed wins

Allogeneic of the shelf ready made therapy which is accessible quick & cost effective 🐭

Active Allogeneic CAR‑T Trials in AML

AVC‑201 (AvenCell) — Allogeneic CD123‑Directed CAR‑T

UCART123 (Cellectis) — Phase 1 Trial

Note: no FDA approval to date as the clinical trials are evolving, Avc-201/CD123 Direct Allogeneic is leading the next generation of AML therapy

the info is out there please Dyor as i have Done mine The homeless hemogenyx mice have a Future:-)))) 🐭

Here you are 🐭

https://www.nature.com/articles/d43747-025-00108-z

Allogene Therapeutics, a clinical-stage biotechnology company in South San Francisco, is rewriting this paradigm with its pioneering allogeneic (AlloCAR T) platform—a scalable, ‘off-the-shelf’ alternative designed to deliver cell therapy faster, more broadly, and at greater consistency than ever before. Today, Allogene is advancing its ALPHA3 trial—the next frontier in allogeneic CAR-T innovation—aimed at not only treating relapse but ultimately preventing it.🐭

Https://source.washu.edu/2026/03/innovative-car-t-cell-therapy-receives-fda-breakthrough-therapy-designation/

A major advantage of the treatment is its “off-the-shelf” availability, eliminating the need to manufacture an individualized cell product for each patient. The cell therapy can be prepared in advance from cells donated by healthy individuals and used to treat any patient with a T-cell cancer. In contrast, already-approved CAR-T cell therapies are adapted from the patient’s own immune cells, a process that typically takes three to four weeks.🐭

reminder the clocks go forward & the hemo clinical trial will follow !

The bulls are speculating their emotions of no substance, one poster claims to have spoken with a broker who was "reassuring" but gave no details whilst others lay low in the shadow of a large spread@ 13.21% the candles are flickering so gentlemen please take a seat at the table as the game is about to start

place your bets ?

Car-t....allogeneic cell therapy is still in the infancy phase as the science R & D Evolves, HG-CT-1 Autologous therapy may be the antidote for scalability the answer is unknown until proven.....so the tech transfer is noise 🐭

What`s an infusion ? a slow injection of substance into the vein🐭

The last raise was saving grace the next enrolment of cohorts will require a cash injection before any infushion🐭

HG‑CT‑1 as a custom, patient‑specific autologous CAR‑T, which cannot be batch‑manufactured or scaled like an allogeneic therapy.

i will come clean it is not the same as CD19-FLT-33/ Autologous proves the biology./ Allogeneic scales the cure/ Autologous provides early revenue potential ;allogeneic unlocks scale and cost efficiency./ Together, they create a future🐭

HG-CT-1 is a clinical term used by Hemogenyx it is the same as CD19-FLT-33.

HG-CT-1/CD19-FLT-33 is a custom therapy and can not be scaled up

🐭

My Dear Darling jhfh you really should lighten up & get on the laughing Gas "HEX"

Hemo therapy is Autologous custom therapy scroll back and read the post & read it again saves typing for a week;

Autologous is not scalable so not under the same umbrella as allogeneic.

the tech transfer "Made" platform is Allogeneic and will require a separate c/trial

Autologous is the fore runner and the data can be used to tweet the allogeneic therapy giving vlad a head start. "Think about it"

scroll back and read the post & read it again.....hemo will be travelling in the right direction when both of the tech is under one umbrella.

in a nutshell "Made"in Heaven:🐭

I am not a robot a researched investor🐭:-)))

Dual revenue curve: early autologous income + mass‑market allogeneic growt

market potencial

Current CAR‑T market: >$5B and growing rapidly

Allogeneic CAR‑T expected to expand the addressable population by 5–10×

Potential to move into earlier‑line therapy, solid tumours, and autoimmune diseases

Global expansion enabled by off‑the‑shelf manufacturing🐭

Wave 2 — Allogeneic CAR‑T (Off‑the‑Shelf Therapy)

Donor‑derived, batch‑manufactured, cryopreserved product

Same CAR architecture as autologous, reducing biological risk

Enables same‑day treatment

Dramatically lowers cost of goods

Scales globally across hospitals and markets

CAR‑T therapy has delivered unprecedented remission rates in blood cancers, yet today’s products remain constrained by:

Slow manufacturing (3–6 weeks from cell collection to infusion)

High cost (£250k–£350k per patient)

Limited access (only specialist centres can deliver treatment)

Inability to scale (each dose is made from each patient’s own cells)

Patients relapse while waiting. Hospitals struggle with logistics. Payers face unsustainable costs.

The world needs a faster, scalable, off‑the‑shelf solution.

solution

Wave 1 — Autologous CAR‑T (Personalised Therapy)

Fastest path to clinical proof

Validates our CAR design and safety profile

Builds treatment‑centre infrastructure

Generates early, high‑margin revenue

Ideal for complex or heavily pre‑treated patients